-+ 0.00%
-+ 0.00%
-+ 0.00%

Novocure Says Optune Pax Receives CE Mark For Treatment Of Adult Patients With Locally Advanced Pancreatic Cancer Of Exocrine Origin, Concomitant With Gem/Nab-Pac

Benzinga·06/30/2026 11:11:50
Listen to the news

The CE Mark is supported by results from the Phase 3 PANOVA-3 trial demonstrating a statistically significant improvement in overall survival (OS) for patients treated with Optune Pax concomitant with gemcitabine and nab-paclitaxel

Treatment with Optune Pax was also shown to significantly delay patients’ pain progression, helping to preserve quality of life

Optune Pax is a first-of-its-kind wearable medical device for the treatment of pancreatic cancerthat delivers Tumor Treating Fields, alternating electric fields that cause cancer cell death

Novocure (NASDAQ:NVCR) announced today that Optune Pax® has received CE (Conformité Européenne) Mark for the treatment of adult patients with locally advanced pancreatic cancer of exocrine origin, concomitant with gemcitabine and nab-paclitaxel (gem/nab-pac) in accordance with guideline recommendations.